Order Article Reprints

Hanauer SB, Torres EA, Aragon-Han P, Chapman JC, Swaminath AC, Arai R, Butnariu M, Lee TC, Rabizadeh S, Check M, et al. The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics. 2025; 17(4):428. https://doi.org/10.3390/pharmaceutics17040428

Hanauer, Stephen B., Esther A. Torres, Patricia Aragon-Han, Jonathon C. Chapman, Arun C. Swaminath, Ronen Arai, Mandalina Butnariu, Thomas C. Lee, Shervin Rabizadeh, Morgan Check, and et al. 2025. "The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program" Pharmaceutics 17, no. 4: 428. https://doi.org/10.3390/pharmaceutics17040428

Hanauer, S. B., Torres, E. A., Aragon-Han, P., Chapman, J. C., Swaminath, A. C., Arai, R., Butnariu, M., Lee, T. C., Rabizadeh, S., Check, M., Barrett, T. A., Hashash, J. G., Meister, T., Yen, E. F., Kinnucan, J., Stein, D. J., Ziring, D., Shaposhnikov, R., Sinh, P., ... Abraham, B. P. (2025). The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics, 17(4), 428. https://doi.org/10.3390/pharmaceutics17040428